Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer | MicrobiomeTrials← Back to trialsNCT04997993
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-12-13Est. Completion: 2027-07
Enrollment target: 23 participants Locations- Icahn School of Medicine at Mount Sinai, New York, New York, United States
Other microbiome trials you might be interested in
Locally Advanced (Inoperable) or Metastatic Breast Cancer
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibit…
Tucson, United StatesEst. completion Nov 1, 2027
Breast CancerMetastatic Breast CancerTriple Negative Breast CancerEstrogen-receptor-positive Breast CancerHormone Receptor Negative Breast Carcinoma
This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patien…
Rochester, United States
Est. completion Jun 2, 2031